Swissmedic Highlights Regulatory Focus on Parenteral Cosmetic Products
Swissmedic has released key insights on parenteral products in the cosmetic sector. This update, published on October 13, 2025, emphasizes […]
FDA Issues Boxed Warning Update for CARVYKTI Over Rare Enterocolitis Risk
The U.S. Food and Drug Administration (FDA) has issued updated labeling for Ciltacabtagene Autoleucel (CARVYKTI), a treatment for certain patients
Urgent FDA Alert: Cybersecurity Vulnerability Identified in Abiomed’s Automated Impella Controller
On October 10, 2025, the FDA issued an alert regarding a cybersecurity vulnerability affecting the Automated Impella Controller (AIC) used
CSMD-Horizon 2025 to Address MedTech AI, Digital Health and Regulation in Brussels
The CSMD-Horizon Special Conference for MedTech AI and Digital Health: Regulation, Market Access and Clinical Evidence will take place on
Swissmedic Grants First Authorization for Balversa® in Targeted Cancer Treatment
On October 10, 2025, Swissmedic issued its first authorization for Balversa®, marking a significant milestone in precision oncology. This pivotal
Swissmedic Approves Extended Use for Spevigo®: Important Regulatory Update
Swissmedic has officially approved an extension of the therapeutic indication for Spevigo®. This regulatory decision marks a refined update to
Swissmedic Grants Initial Authorization for Voxzogo®: A Milestone for Regulatory Compliance
Swissmedic, the Swiss agency for therapeutic products, has officially granted the first authorization for Voxzogo®, marking a significant step forward
Swissmedic Announces First Authorization for Blenrep®
Swissmedic has officially announced the first authorization of Blenrep®, marking a significant regulatory milestone in its approval process. Clinical, quality,
Emerging Evidence: Heavy Metal Exposure and Respiratory Health Risks from Vaping in Young Adults
On October 11, 2025, researchers at Ohio State University Comprehensive Cancer Center revealed a new clinical trial initiative to investigate
Exploring High-Intensity Interval Training and Time-Restricted Eating: New Study Targets Type 2 Diabetes Risk Management
A groundbreaking clinical trial now recruiting aims to compare the impacts of High-Intensity Interval Training (HIIT) and Time-Restricted Eating (TRE)